TY - JOUR AU - Holland, Peter J. AU - Tappen, Ruth M. AU - Newman, David O. AU - Freeman-Costin, Katherine C. AU - Fisher, Lori J. PY - 2021/12/01 Y2 - 2024/03/28 TI - Effect of Memantine on Prolonging Safe Driving in Early AD: a Pilot Study JF - Canadian Geriatrics Journal JA - Can Geriatr J VL - 24 IS - 4 SE - Original Research DO - 10.5770/cgj.24.540 UR - https://cgjonline.ca/index.php/cgj/article/view/540 SP - 292-296 AB - <p class="p2"><span class="s1"><span class="Apple-converted-space"> </span></span><strong>Background<span class="Apple-converted-space"> </span></strong></p><p class="p3">To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD.<span class="Apple-converted-space"> </span></p><p class="p4"><strong>Methods<span class="Apple-converted-space"> </span></strong></p><p class="p3">A placebo-controlled, double blind randomized trial was conducted. Forty-three individuals ≥60 with mild AD met screening criteria and were randomized. Driving ability was measured by a standardized on-road driving test. Outcomes were driving capacity at 6 and 12 months and completion of the 12-month intervention.<span class="Apple-converted-space"> </span></p><p class="p4"><strong>Results<span class="Apple-converted-space"> </span></strong></p><p class="p3">Of 43 participants randomized, 59% of the memantine group and 52% of the placebo group completed the on-road test at 12 months (<em>p </em>= .66). All 13 memantine group participants maintained their driving status at 12 months, whereas only 8 of the 11 placebo group participants did (<em>p </em>= .040, OR = 4.45).<span class="Apple-converted-space"> </span></p><p class="p4"><strong>Conclusions<span class="Apple-converted-space"> </span></strong></p><p class="p3">Results provide the framework for designing a rigorous multisite clinical trial of memantine effect on maintaining driving capacity in mild AD.<span class="Apple-converted-space"> </span></p> ER -